FERROUS CHLORIDE

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2Cl.Fe
Molecular Weight	126.751
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Cl-].[Cl-].[Fe++]

InChI

InChIKey=NMCUIPGRVMDVDB-UHFFFAOYSA-L

InChI=1S/2ClH.Fe/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula	Fe
Molecular Weight	55.845
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502
Curator's Comment: description was created based on several sources, including http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en

Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Anemia 68 Sources: http://www.medicatione.com/?c=ing&s=ferrous%20aspartate	Palliative	Not Provided 504	Unknown Approved Use Unknown
Unknown 2578
Hypochromic anemia 36 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16694502	Palliative	Not Provided 504	Unknown Approved Use Unknown
Unknown 2578
Unknown 2578
Unknown 2578
Iron deficiency 80 Sources: http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en	Primary	Approved 8429	Ferro Sanol Duodenal Approved Use Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Unknown 2578

PubMed

Title	Date	PubMed
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS.	1932 Jul 1	17815234
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.	1932 Nov 11	17744342
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.	1932 Sep 30	17754111
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.	1937 Jul	16694502
[Ferrous lactate as an oral iron preparation for therapeutic use].	1954 Nov 27	14348915
Clinical appraisal of drugs with special reference to a new chelate hematinic.	1957 Jul 11	13452048
[FERROUS ASPARTATE IN THERAPY].	1964 Jan 1	14116934
[Historical notes on the therapy of depression].	1986 Nov 22	3541174
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.	1997 Oct	9408841
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.	2007	17426393
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice.	2009	19421372
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study.	2009 Nov 15	19586718
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.	2010 Dec	20039148
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.	2011 Jun 10	21439359
Tolerability of different oral iron supplements: a systematic review.	2013 Apr	23252877
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows.	2013 Jul	23660146
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.	2014	25402762
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes.	2015 Jun 22	25981197
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.	2017 Jul 5	28371713
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes.	2017 Mar 13	28170144
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle.	2017 May 1	28249212

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:30:58 GMT 2023` Edited by `admin` on `Fri Dec 15 15:30:58 GMT 2023`
Record UNII	S3Y25PHP1W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FERROUS CHLORIDE

Common Name

English

FERROUS CHLORIDE [HSDB]

Common Name

English

FERROUS CHLORIDE [MART.]

Common Name

English

FERROUS CHLORIDE [MI]

Common Name

English

IRON(II) CHLORIDE

Systematic Name

English

Ferrous chloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QB03AA05